Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment

Siqiang Lai, Min Zhang, Dongsheng Xu, Yiying Zhang, Lisha Qiu, Changhai Tian, Jialin Charlie Zheng

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.

Original languageEnglish
Article number7
JournalTranslational Neurodegeneration
Issue number1
StatePublished - Apr 18 2015

Bibliographical note

Publisher Copyright:
© Lai et al.; licensee BioMed Central.


  • Alzheimer's disease
  • Induced neural progenitor cells
  • Stem cell-based therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Direct reprogramming of induced neural progenitors: A new promising strategy for AD treatment'. Together they form a unique fingerprint.

Cite this